title: Lipoprotein apheresis in the treatment of dyslipidaemia - the Czech Republic experience.
abstract: In 1984, we started using therapeutic plasmapheresis (plasma exchange) as a method of extracorporeal lipoprotein elimination for the treatment of hypercholesterolemic patients. We evaluated the results of long-term therapy in 14 patients, 8 men and 6 women. The average age was 55.6+/-13.2 (range 28-70), median 59.5 years. 14 patients were diagnosed with familial hypercholesterolemia (FH): 5 homozygous, 9 heterozygous. Ten patients in the group were treated using immunoadsorption lipoprotein apheresis and 4 using hemorheopheresis. Immunoapheretic interventions decreased LDL-cholesterol (82+/-1 %), ApoB (73+/-13 %) and even Lp(a) by 82+/-19 %, respectively. Selected non-invasive methods are important for long-term and repeated follow-up. Carotid intima-media thickness showed improvement or stagnation in 75 % of the patients. Biomarkers of endothelial dysfunction such as endoglin (in the control group: 3.85+/-1.25 microg/l, in lipoprotein apheresis-treated hypercholesterolemic individuals 5.74+/-1.47 microg/l), CD40 ligand (before lipoprotein apheresis: 6498+/-2529 ng/l, after lipoprotein apheresis: 4057+/-2560 ng/l) and neopterin (before lipoprotein apheresis: 5.7+/-1.1 nmol/l, after lipoprotein apheresis: 5.5+/-1.3 nmol/l) related to the course of atherosclerosis, but did not reflect the actual activity of the disease nor facilitate the prediction or planning of therapy. Hemorheopheresis may improve blood flow in microcirculation in familial hypercholesterolemia and also in some other microcirculation disorders via significantly decreased activity of thrombomodulin (p<0.0001), tissue factor (p<0.0001), aggregation of thrombocytes (p<0.0001) and plasma and whole blood viscosity (p<0.0001). In conclusion, lipoprotein apheresis and hemorheopheresis substantially lowered LDL-cholesterol in severe hypercholesterolemia. Our experience with long-term therapy also shows good tolerance and a small number of complications (6.26 % non-serious clinical complications).
authors.affiliation: Third Department of Internal Medicine, Metabolism and Gerontology, University Hospital Hradec Králové and Charles University Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic. blaha@lfhk.cuni.cz.
authors.forename: V
authors.initials: V
authors.lastname: Bláha
authors.forename: M
authors.initials: M
authors.lastname: Bláha
authors.forename: M
authors.initials: M
authors.lastname: Lánská
authors.forename: D
authors.initials: D
authors.lastname: Solichová
authors.forename: L
authors.initials: L
authors.lastname: Kujovská Krčmová
authors.forename: E
authors.initials: E
authors.lastname: Havel
authors.forename: P
authors.initials: P
authors.lastname: Vyroubal
authors.forename: Z
authors.initials: Z
authors.lastname: Zadák
authors.forename: P
authors.initials: P
authors.lastname: Žák
authors.forename: L
authors.initials: L
authors.lastname: Sobotka
mesh_terms: D000328:Adult; D000368:Aged; D001781:Blood Component Removal / Q000379:methods*; D059168:Carotid Intima-Media Thickness; D008078:Cholesterol, LDL / Q000097:blood*; D018153:Czech Republic / Q000453:epidemiology; D050171:Dyslipidemias / Q000097:blood* / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D008078:Cholesterol, LDL; D008074:Lipoproteins